Related Experiment Video
Updated: Apr 23, 2026
Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
Published on: August 6, 2021
[Network pharmacology study of mechanism on xuesaitong injection against retinal vein occlusion]
Abstract:
Retinal vein occlusion (RVO) is a common clinical disease causing vision loss. Risk factors such as diabetes, atherosclerosis are closely associated with RVO. Xuesaitong injection is used extensively in clinical treatment of RVO, however the mechanism is still unclear. In this study, we investigated the protective effect of Xuesaitong injection on RVO rat model. Using a compound-target network of Xuesaitong on anti-RVO constructed by literature mining, we aim to elucidate the multi-compound, multi-target effect of Xuesaitong injection. Fifteen potential targets of Xuesaitong injection associated with inflammation, angiogenesis, apoptosis, and coagulation were identified in this study. VEGF, IL-1beta and IL-6, three important targets in the compound-target network were further experimentally validated. This study provided experimental evidence for Xuesaitong injection being effective in treating RVO and a network view on its anti-RVO mode of action through a multi-compound and multiple-target mechanism.
Insights
Xuesaitong injection shows protective effects against retinal vein occlusion (RVO) in rats. This study elucidates its multi-target mechanism involving inflammation, angiogenesis, and coagulation pathways.
Area of Science:
- Pharmacology
- Ophthalmology
- Traditional Chinese Medicine
Context:
- Retinal vein occlusion (RVO) is a prevalent cause of vision loss, often linked to diabetes and atherosclerosis.
- Xuesaitong injection is widely used for RVO, but its therapeutic mechanisms remain incompletely understood.
Purpose:
- To investigate the protective effects of Xuesaitong injection on a rat model of retinal vein occlusion (RVO).
- To elucidate the multi-compound, multi-target mechanism of Xuesaitong injection in treating RVO using a compound-target network analysis.
Summary:
- A compound-target network identified 15 potential targets of Xuesaitong injection related to inflammation, angiogenesis, apoptosis, and coagulation.
- Vascular Endothelial Growth Factor (VEGF), Interleukin-1 beta (IL-1β), and Interleukin-6 (IL-6) were experimentally validated as key targets.
- The study provides evidence for Xuesaitong injection's efficacy in RVO treatment via a network-based, multi-target approach.
Impact:
- Offers experimental validation for the clinical use of Xuesaitong injection in managing RVO.
- Provides a network-based understanding of Xuesaitong's anti-RVO mode of action.
- Highlights the potential of multi-target therapies in ophthalmological diseases.
